CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(04): 390-397
DOI: 10.1055/a-1330-7514
GebFra Science
Statement/Stellungnahme

Recommendations of the AGG (Task Force for Obstetrics, Section Maternal Diseases) on the Management of Maternal Hepatitis B, C and D Infection in Pregnancy

Artikel in mehreren Sprachen: English | deutsch
Maritta Kühnert
1   Geburtshilfe, UFK Marburg, Marburg, Germany
,
Sven Kehl
2   Frauenklinik, Friedrich Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
,
Ulrich Pecks
3   Frauenklinik, UKSH, Kiel, Germany
,
Ute Margaretha Schäfer-Graf
4   Klinik für Gynäkologie und Geburtshilfe, St. Joseph Krankenhaus, Berlin, Germany
,
Tanja Groten
5   Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Jena, Jena, Germany
,
Ralf Lothar Schild
6   Klinik für Geburtshilfe und Perinatalmedizin, Diakovere Perinatalzentrum Hannover, Hannover, Germany
,
Dietmar Schlembach
7   Klinik für Geburtsmedizin, Vivantes Klinikum Neukölln-Berlin, Berlin, Germany
,
Markus Schmidt
8   Klinik für Frauenheilkunde und Geburtshilfe, Sana Kliniken Duisburg GmbH, Duisburg, Germany
,
Amr Hamza
9   Gynäkologie und Geburtshilfe, Universitätsklinikum des Saarlandes, Homburg, Germany
› Institutsangaben

Abstract

These statements and recommendations should provide appropriate information about maternal and fetal routes of infection, screening, detection of risk factors, diagnostic procedures, treatment, birth planning and peripartum and postpartum management of maternal hepatitis infection and offer pointers for prenatal counselling and routine clinical care on delivery wards.



Publikationsverlauf

Eingereicht: 26. November 2020

Angenommen nach Revision: 02. Dezember 2020

Artikel online veröffentlicht:
14. April 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References/Literatur

  • 1 Society for Maternal-Fetal Medicine (SMFM). Dionne-Odom J, Tita ATN, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol 2016; 214: 6-14
  • 2 Yi W, Pan CQ, Hao J. et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014; 60: 523-529
  • 3 Greenup AJ, Tan PK, Nguyen V. et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014; 61: 502-507
  • 4 Chang MH, Chen CJ, Lai MS. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859
  • 5 Brown jr. RS, Verna EC, Pereira MR. et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol 2012; 57: 953-959
  • 6 Yang J, Zeng XM, Men YL. et al. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus–a systematic review. Virol J 2008; 5: 100
  • 7 Mast EE, Weinbaum CM, Fiore AE. et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33 quiz CE1–CE4
  • 8 Chen HL, Chang MH, Ni YH. et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 1996; 276: 906-908
  • 9 Robert Koch-Institut. Impfempfehlungen der Ständigen Impfkommission (Stiko), Stand 2019/20. Epidemiol Bull 2019; 34: 313-352
  • 10 Hill JB, Sheffield JS, Kim MJ. et al. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002; 99: 1049-1052
  • 11 American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007; 110: 941-956
  • 12 World Health Organization. Guidelines for the screening, care, and treatment of persons with chronic hepatitis C infection. Accessed July 12, 2017 at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en
  • 13 Wijarnpreecha K, Thongprayoon C, Sanguankeo A. et al. Hepatitis C infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017; 41: 39-45
  • 14 Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol 2017; 217: B2-B12
  • 15 Benova L, Mohamoud YA, Calvert C. et al. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59: 765-773
  • 16 Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010; 14: 169-176
  • 17 Gagnon A, Davies G, Wilson RD. Genetics Committee. Prenatal invasive procedures in women with hepatitis B, hepatitis C, and/or human immunodeficiency virus infections. J Obstet Gynaecol Can 2014; 36: 648-655
  • 18 Kim DK, Riley LE, Harriman KH. et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older – United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66: 136-138
  • 19 Spera AM, Eldin TK, Tosone G. et al. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?. World J Hepatol 2016; 8: 557-565
  • 20 Sarrazin C, Zimmermann T, Berg T. et al. S3-Leitlinie „Prophy­laxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“ AWMF-Register-Nr.: 021/012. Z Gastroenterol 2018; 56: 756-838 doi:10.1055/a-0599-1320
  • 21 Mok J, Pembrey L, Tovo PA. et al. When does mother to child transmission of hepatitis C virus occur?. Arch Dis Child Fetal Neonatal Ed 2005; 90: F156-F160
  • 22 Mast EE, Hwang LY, Seto DS. et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192: 1880-1889
  • 23 Checa Cabot CA, Stoszek SK, Quarleri J. et al. NICHD International Site Development Initiative Perinatal/Longitudinal Study in Latin American Countries Study Group. Mother-to-Child Transmission of Hepatitis C Virus (HCV) Among HIV/HCV-Coinfected Women. J Pediatric Infect Dis Soc 2013; 2: 126-135
  • 24 Snijdewind IJ, Smit C, Schutten M. et al. Low mother-to-child-transmission rate of Hepatitis C virus in cART treated HIV-1 infected mothers. J Clin Virol 2015; 68: 11-15
  • 25 European Paediatric Hepatitis C Virus Network. A significant sex–but not elective cesarean section–effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192: 1872-1879
  • 26 Ceci O, Margiotta M, Marello F. et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001; 33: 570-575
  • 27 Ohto H, Terazawa S, Sasaki N. et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330: 744-750
  • 28 McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev 2006; (04) CD005546
  • 29 Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection–not a vanishing disease in Europe!. Hepatology 2007; 45: 1331-1332 author reply 1332–1333
  • 30 Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40
  • 31 Shattock AG, Morris MC. Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies. J Clin Microbiol 1991; 29: 1873-1876
  • 32 Mederacke I, Bremer B, Heidrich B. et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48: 2022-2029
  • 33 Castelnau C, Le Gal F, Ripault MP. et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-735
  • 34 Le Gal F, Gordien E, Affolabi D. et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005; 43: 2363-2369
  • 35 Lau JY, Smith HM, Chaggar K. et al. Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection. J Med Virol 1991; 33: 273-276 doi:10.1002/jmv.1890330412
  • 36 Seto MTN, Cheung KW, Hung IFN. Management of viral hepatitis A, C, D and E in pregnancy. Best Pract Res Clin Obstet Gynaecol 2020; 68: 44-53 doi:10.1016/bpobgyn.2020.03.009